Cited by 662Bone Metabolism and DiseasesMesenchymal stem cell researchBone Tissue Engineering Materials

Effects of dexamethasone, ascorbic acid and β-glycerophosphate on the osteogenic differentiation of stem cells in vitro

Open access
Langenbach, Fabian, Handschel, Jörg·2013·Stem Cell Research & Therapy

Abstract

The standard procedure for the osteogenic differentiation of multipotent stem cells is treatment of a confluent monolayer with a cocktail of dexamethasone (Dex), ascorbic acid (Asc) and β-glycerophosphate (β-Gly). This review describes the effects of these substances on intracellular signaling cascades that lead to osteogenic differentiation of bone marrow stroma-derived stem cells. We conclude that Dex induces Runx2 expression by FHL2/β-catenin-mediated transcriptional activation and that Dex enhances Runx2 activity by upregulation of TAZ and MKP1. Asc leads to the increased secretion of collagen type I (Col1), which in turn leads to increased Col1/α2β1 integrin-mediated intracellular signaling. The phosphate from β-Gly serves as a source for the phosphate in hydroxylapatite and in addition influences intracellular signaling molecules. In this context we give special attention to the differences between dystrophic and bone-specific mineralization.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/scrt328

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Silk fibroin can trigger Wnt/beta-catenin signaling pathway-dependent Runx2 expression in osteoprogenitor cells without dexamethasone additives.

    “These results indicate that silk fibroin can trigger Wnt/β-catenin signaling pathway-dependent Runx2 expression in osteoprogenitor cells without dexamethasone additives [34].”

    From Recent Advances in Silk Fibroin-Based Composites for Bone Repair Applications: A Review (2025) · cites this paper as [34]

    The Dexamethasone section (page unavailable) describes Wnt/β-catenin-dependent Runx2 expression in osteogenic differentiation. It attributes the mechanism to dexamethasone-induced FHL2 activity, however, and does not report that silk fibroin triggers it without dexamethasone. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Significant mineral deposition was observed when silk fibroin was co-cultured with rat bone marrow mesenchymal stem cells in vitro for 12 days.

    “Significant mineral deposition was observed when silk fibroin was co-cultured with rat bone marrow mesenchymal stem cells (BMSCs) in vitro for 12 days.”

    From Recent Advances in Silk Fibroin-Based Composites for Bone Repair Applications: A Review (2025) · cites this paper as [34]

    The Introduction and β-Glycerophosphate section discuss osteogenic differentiation and mineralization generally, but do not describe the claimed experiment. Searches for silk fibroin, rat BMSCs, and 12-day mineral deposition found no passage addressing that result in our copy. (LLM, conf=0.77)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Langenbach, F., & Handschel, J.
Affiliations
Heinrich Heine University Düsseldorf (DE)
Corresponding author
Langenbach, Fabian
Venue
Stem Cell Research & Therapy
Published
2013-09-30
Volume
4
Issue
5
Pages
117-117
ISSN
1757-6512 (ISSN-L)
OpenAlex
W2033524865
Cited by
662
References
53
Citations by year
2026: 41 · 2025: 69 · 2024: 59 · 2023: 63 · 2022: 68 · 2021: 82 · 2020: 62 · 2019: 56 · 2018: 40 · 2017: 53 · 2016: 41 · 2015: 16 · 2014: 12
FWCI
2.12
Type
journal article
Language
en
Open access
Locations
  • Stem Cell Research & Therapy (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Deutsche Forschungsgemeinschaft
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Physical Sciences › Engineering › Biomedical Engineering › Bone Tissue Engineering Materials
Keywords
osteogenic differentiation, dexamethasone, vitamin C, beta-glycerophosphate, mesenchymal stem cells, Runx2, FHL2, β-catenin, TAZ, MKP-1, type I collagen, hydroxyapatite, intracellular signaling
MeSH terms
Ascorbic Acid, Bone Marrow Cells, Dexamethasone, Glycerophosphates, Humans, Osteogenesis, Signal Transduction, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review